This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Astrogenetix Performs Drug Development In Microgravity

AUSTIN, Texas, May 26, 2010 (GLOBE NEWSWIRE) -- Space Shuttle Atlantis returned from the International Space Station (ISS) landing at the Kennedy Space Center this morning with the tenth scientific payload for Astrogenetix, a commercial biotech company based out of Austin, Texas. Astrogenetix is conducting research on methicillin-resistant Staphylococcus aureus (MRSA) as part of the ISS National Laboratory Pathfinder Vaccine (NLP-V) missions.

"By removing a force as fundamental as gravity in the course of this research, we're witnessing bacteria grow in ways that have not been demonstrated on Earth," said John Porter, Chief Executive Officer of Astrogenetix. "The use of microgravity as a new research platform will bring meaningful advancements in drug discovery and development, and we believe this early vaccine work is just the beginning."

The Company is utilizing the unique conditions of microgravity to uncover changes in bacteria, which can be targeted to create new vaccines and therapeutics. Astrogenetix has identified target genes for MRSA virulence by growing the bacteria in the microgravity environment during previous NLP-V. The Company is conducting controls on this flight to validate prior research by sending up several different strains of the bacteria, which were genetically altered to remove target genes that are believed to be associated with virulence of this organism. Additionally, the Company is bringing back live forms of the bacteria that were grown in microgravity to compare to ground-based samples of the bacteria. The science team will perform post-flight analysis on the microbes to evaluate the changes that occurred on this mission.

"Each flight opportunity allows us to learn more about the bacteria and the changes that are occurring as they grow in space," added Dr. Jeanne Becker, Chief Science Officer for Astrogenetix. "The knowledge we're gaining can be applied to streamline and accelerate the development of vaccines and therapeutics on Earth."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ASTC $1.85 1.20%
AAPL $92.40 -0.90%
FB $119.29 1.30%
GOOG $708.50 1.00%
YHOO $37.05 0.30%


Chart of I:DJI
DOW 17,685.39 +24.68 0.14%
S&P 500 2,046.99 -3.64 -0.18%
NASDAQ 4,701.3840 -15.71 -0.33%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs